Management and Prevention of Bone Complications Supportive Care


Xgeva Approved for Patients with Bone Metastases (11-30-2010)

Xgeva™ (denosumab) has been approved by the US Food and Drug Administration (FDA) for the prevention of bone complications such as fracture in patients with bone metastases from solid (not blood-related) cancers. It is not approved for patients with... Continue Reading